Earnings Review and Free Research Report: Pluristem Announced Fiscal 2017 Results

LONDON, UK / ACCESSWIRE / September 29, 2017 / Pro-Trader Daily has just published a free post-earnings coverage on Pluristem Therapeutics Inc. (NASDAQ: PSTI) (“Pluristem”), which can be viewed by registering at http://protraderdaily.com/optin/?symbol=PSTI, following the Company’s disclosure of its financial results on September 11, 2017, for the fourth quarter of the fiscal year 2017. The Company received an $8.7 million non-dilutive grant from the European Union’s Horizon 2020 Program. Our daily stock reports are accessible for free, and with those to look forward today you also will be signing up for a complimentary member’s account at:

http://protraderdaily.com/register/

At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on PSTI. With the links below you can directly download the report of your stock of interest free of charge at:

http://protraderdaily.com/optin/?symbol=PSTI

Earnings Reviewed

Pluristem did not recognize revenues in FY17 compared to revenues of $2.847 million and $379,000 for the fiscal years ended June 30, 2016, and June 30, 2015, respectively. All revenues in the fiscal year 2016 and fiscal year 2015 were derived from a prior license agreement with United Therapeutics Corp.

During FY17, Pluristem’s G&A expenses increased 6.7% to $6.93 million from $6.49 million in FY16. During the year, the Company’s net R&D expenses increased 7.7% to $21.09 million from $19.58 million in FY16.

During FY17, Pluristem’s operating loss was $28.02 million compared to an operating loss of $23.32 million in FY16.

During FY17, Pluristem’s net loss was $27.81 million compared to a net loss of $23.25 million in FY16. During FY17, Pluristem’s diluted earnings per share (EPS) was negative $0.32 compared to a negative diluted EPS of $0.29 in FY16.

During Q4 FY17, Pluristem received approval for a $1.5 million grant from the Israel Innovation Authority to support the PLX-PAD program and was also awarded a Smart Money grant from Israel’s Ministry of Economy and Industry to advance its product candidates towards marketing in the China-Hong Kong markets. The Company’s PLX-R18 Program also received $900,000 in funding from the Israel-US Binational Industrial Research and Development Foundation (BIRD) for a collaborative study with the New York Blood Center on umbilical cord blood transplantation.

In August 2017, the Company announced that the US DOD will examine whether PLX-R18 administered prior to, or within the first 24 hours of exposure to radiation will mitigate ARS.

On September 05, 2017, Pluristem received an $8.7 million non-dilutive grant from the European Union’s Horizon 2020 program for the Company’s planned Phase-III study to support recovery following surgery for hip fracture.

Balance Sheet

As of June 30, 2017, Pluristem’s cash and cash equivalents decreased 24.2% to $4.71 million from $6.22 million in FY16.

During FY17, the Company’s total assets decreased 18.3% to $37.53 million from $45.94 million in FY16.

During FY17, the Company’s trade payables decreased 27.3% to $1.97 million from $2.71 million in FY16.

During FY17, the Company’s accrued expenses increased 7.2% to $1.47 million from $1.37 million in FY16.

During FY17, the Company’s cash used for operating activities was $21.61 million compared to $18.52 million in FY16.

Outlook

For FY18, Pluristem expects to complete a partnership deal in Asia; continued development of the ARS project including 3rd party funding of pivotal studies from the US government; expected data readouts from several clinical trials; launch of its phase-III study for hip fracture; preparations for Biological License Application (BLA) submission in ARS; and meeting enrollment goals for its CLI study.

Stock Performance

On Thursday, September 28, 2017, the stock closed the trading session at $1.51, dropping 2.58% from its previous closing price of $1.55. A total volume of 255.47 thousand shares have exchanged hands. Pluristem Therapeutics’ stock price surged 26.89% in the last one month, 17.05% in the past three months, and 24.79% in the previous six months. Furthermore, since the start of the year, shares of the Company have gained 5.59%. The stock currently has a market cap of $149.43 million.

Pro-Trader Daily:

Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charter-holder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: contact@protraderdaily.com

Phone number: (917) 341.4653

Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily

ReleaseID: 476649